Daxor BVA Gets FDA Clearance, Celebrates Nasdaq Listing Milestone

Daxor Corporation celebrates FDA 510(k) clearance for its patent-pending Daxor BVA, a rapid, compact, and hand-held blood volume analyzer. The milestone marks a major achievement for the company, which aims to address the healthcare crisis of inaccurate blood volume measurement. The official replay of the Nasdaq Closing Bell Ceremony is available, and the company invites visitors to learn more about its innovative technology.

Daxor Corporation (NASDAQ: DXR) has achieved a significant milestone in the medical technology sector with the FDA 510(k) clearance for its patent-pending Daxor BVA™, a rapid, compact, and hand-held blood volume analyzer. The device, which has been under development in collaboration with the U.S. Department of Defense, promises to revolutionize fluid management in clinical settings by providing precise and rapid blood volume measurements [1].

The Daxor BVA™ device quantifies a patient’s blood volume against patient-specific norms, delivering critical data for precise fluid management across various medical conditions. This innovation addresses a critical gap in healthcare, where clinicians previously relied on imprecise methods for assessing fluid status [2].

The FDA 510(k) clearance is a significant step for Daxor Corporation, which has already conducted over 75,000 tests with its previous BVA-100™ system. The new BVA™ device processes results three times faster than its predecessor while maintaining laboratory-grade diagnostic precision in a lightweight 7-pound package that can be easily moved between clinical settings [1].

The economic burden of conditions requiring accurate fluid management, such as heart failure, critical care needs, sepsis, dialysis, and traumatic injuries, is substantial. The Daxor BVA™ device aims to address this need by providing accurate and rapid blood volume measurements, which can significantly improve patient outcomes [1].

Clinical studies have demonstrated the clinical benefits of blood volume analysis-guided care. For instance, an 86% reduction in one-year mortality for heart failure patients, shorter hospital stays, 56% fewer readmissions, and lower healthcare costs have been observed with BVA-guided care [1].

The official replay of the Nasdaq Closing Bell Ceremony, where Daxor Corporation celebrated this achievement, is available. The company invites visitors to learn more about its innovative technology and the potential it holds for transforming clinical practices [2].

References:
[1] https://za.investing.com/news/stock-market-news/daxor-stock-soars-after-fda-clearance-for-new-blood-volume-analyzer-93CH-3825839
[2] https://www.nasdaq.com/events/daxor-corporation-rings-closing-bell